A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

December 22, 2016

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

Sabin mOPV2

"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Fidec Corporation

OTHER